Buspirone Hydrochloride (Page 4 of 4)
OVERDOSAGE
Signs and Symptoms:
In clinical pharmacology trials, doses as high as 375 mg/day were administered to healthy male volunteers. As this dose was approached, the following symptoms were observed: nausea, vomiting, dizziness, drowsiness, miosis, and gastric distress. A few cases of overdosage have been reported, with complete recovery as the usual outcome. No deaths have been reported following overdosage with buspirone hydrochloride tablets alone. Rare cases of intentional overdosage with a fatal outcome were invariably associated with ingestion of multiple drugs and/or alcohol, and a causal relationship to buspirone could not be determined. Toxicology studies of buspirone yielded the following LD50 values: mice, 655 mg/kg; rats, 196 mg/kg; dogs, 586 mg/kg; and monkeys, 356 mg/kg. These dosages are 160 to 550 times the recommended human daily dose.
Recommended Overdose Treatment:
General symptomatic and supportive measures should be used along with immediate gastric lavage. Respiration, pulse, and blood pressure should be monitored as in all cases of drug overdosage. No specific antidote is known to buspirone, and dialyzability of buspirone has not been determined.
DOSAGE AND ADMINISTRATION
The recommended initial dose is 15 mg daily (7.5 mg b.i.d.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day, as needed. The maximum daily dosage should not exceed 60 mg per day. In clinical trials allowing dose titration, divided doses of 20 mg to 30 mg per day were commonly employed.
The bioavailability of buspirone is increased when given with food as compared to the fasted state (see CLINICAL PHARMACOLOGY). Consequently, patients should take buspirone in a consistent manner with regard to the timing of dosing; either always with or always without food.
When buspirone is to be given with a potent inhibitor of CYP3A4, the dosage recommendations described in the PRECAUTIONS: DRUG INTERACTIONS section should be followed.
Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Antidepressant
At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with buspirone hydrochloride tablets. Conversely, at least 14 days should be allowed after stopping buspirone hydrochloride tablets before starting an MAOI antidepressant CONTRAINDICATIONS and DRUG INTERACTIONS).
Use of Buspirone Hydrochloride Tablets with (Reversible) MAOIs, Such as Linezolid or Methylene Blue
Do not start buspirone hydrochloride tablets in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, non-pharmacological interventions, including hospitalization, should be considered (see CONTRAINDICATIONS and DRUG INTERACTIONS).
In some cases, a patient already receiving therapy with buspirone hydrochloride tablets may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, buspirone hydrochloride tablets should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with buspirone hydrochloride tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS).
The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg per kg with buspirone hydrochloride tablets is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use (see CONTRAINDICATIONS, WARNINGS and DRUG INTERACTIONS).
HOW SUPPLIED
Buspirone Hydrochloride Tablets USP, 5 mg are white to off-white, capsule-shaped, flat- faced, beveled-edge tablets debossed with bisect on one side; one side of bisect is debossed with ‘ZE’ and another is debossed with ’36’ and other side is plain and are supplied as follows:
NDC 68382-180-01 in bottle of 100 tablets
NDC 68382-180-05 in bottle of 500 tablets
NDC 68382-180-10 in bottle of 1000 tablets
NDC 68382-180-30 in blister pack of 100 unit-dose tablets
Buspirone Hydrochloride Tablets USP, 10 mg are white to off-white, capsule-shaped, flat-faced, beveled-edge tablets debossed with bisect on one side; one side of bisect is debossed with ‘ZE’ and another is debossed with ’37’ and other side is plain and are supplied as follows:
NDC 68382-181-01 in bottle of 100 tablets
NDC 68382-181-05 in bottle of 500 tablets
NDC 68382-181-10 in bottle of 1000 tablets
NDC 68382-181-30 in blister pack of 100 unit-dose tablets
Buspirone Hydrochloride Tablets USP, 15 mg are white to off-white, capsule-shaped, flat-faced, beveled-edge tablets, bisected on one side and trisected on other side. The trisected side of tablet is debossed with ‘5’ on each trisect segment. The bisected side is debossed with ‘ZE’, on one bisect and ’38’ on other bisect segment and are supplied as follows:
NDC 68382-182-14 in bottle of 60 tablets
NDC 68382-182-01 in bottle of 100 tablets
NDC 68382-182-28 in bottle of 180 tablets
NDC 68382-182-05 in bottle of 500 tablets
NDC 68382-182-10 in bottle of 1000 tablets
NDC 68382-182-30 in blister pack of 100 unit-dose tablets
Buspirone Hydrochloride Tablets USP, 30 mg are white to off-white, capsule-shaped, flat-faced, beveled-edge tablets, bisected on one side and trisected on other side. The trisected side of tablet is debossed with ’10’ on each trisect segment. The bisected side is debossed with ‘ZE’, on one bisect and ’39’ on other bisect segment and are supplied as follows:
NDC 68382-183-14 in bottle of 60 tablets
NDC 68382-183-05 in bottle of 500 tablets
NDC 68382-183-10 in bottle of 1000 tablets
NDC 68382-183-30 in blister pack of 100 unit-dose tablets
Storage:
Store at 20° to 25° C (68° to 77° F) [See USP Controlled Room Temperature].
Dispense in a tight, light-resistant container.
REFERENCE
American Psychiatric Association, Ed.: Diagnostic and Statistical Manual of Mental Disorders—III, American Psychiatric Association, May 1980.
Desyrel® is the registered trademark of Bristol Myers Squibb Company.
Synthroid® is the registered trademark of Abbott Laboratories
SPL UNCLASSIFIED SECTION
Manufactured by:
Cadila Healthcare Ltd.
Ahmedabad, India
Distributed by:
Zydus Pharmaceuticals USA Inc.
Pennington, NJ 08534
Rev.: 12/16
MEDICATION GUIDE
Patient Instruction Sheet
Buspirone Hydrochloride Tablets, USP
HOW TO USE
For 15 mg and 30 mg tablets
Response to buspirone varies among individuals. Your physician may find it necessary to
adjust your dosage to obtain the proper response.
Each tablet is scored and can be broken accurately to provide any of the following dosages.
[Figure]
To break a tablet accurately and easily, hold the tablet between your thumbs and index fingers close to the appropriate tablet score (groove) as shown in the photo. Then, with the tablet score facing you, apply pressure and snap the tablet segments apart (segments breaking incorrectly should not be used).
[figure]
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
SPL UNCLASSIFIED SECTION
Manufactured by:
Cadila Healthcare Ltd.
Ahmedabad, India
Distributed by:
Zydus Pharmaceuticals USA Inc.
Pennington, NJ 08534
Rev.: 06/12
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
BUSPIRONE HYDROCHLORIDE buspirone hydrochloride tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
Labeler — RedPharm Drug, Inc. (828374897) |
Establishment | |||
Name | Address | ID/FEI | Operations |
RedPharm Drug, Inc. | 828374897 | repack (67296-1520) |
Revised: 01/2022 RedPharm Drug, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/buspirone-hydrochloride-58/page/4/